Literature DB >> 35175580

Serum concentrations of free indoxyl and p-cresyl sulfate are associated with mineral metabolism variables and cardiovascular risk in hemodialysis patients.

Teresa Arcidiacono1, Lorenza Macrina1,2, Simone Premaschi3, Arianna Bologna1,2, Giulia Magni1,2, Nadia Foligno1,2, Monica Avino1,2, Cristina Belloni3, Nicola Palmieri4, Ferruccio Conte4, Sergio Bisegna4, Marco Simonini1, Giorgio Slaviero1, Massimo Locatelli3, Giuseppe Vezzoli5,6.   

Abstract

BACKGROUND: Indoxyl sulfate (IS) and p-cresyl sulfate (PCS) are uremic toxins associated with cardiovascular outcome in CKD patients. The present work is an analysis of the association of serum free, total IS and PCS with cardiovascular events and calcium-phosphate metabolism variables in hemodialysis patients.
METHODS: Serum levels of total and free IS and PCS were measured in 139 hemodialysis patients. Their relationship with calcium-phosphate metabolism variables were tested in an observational cohort study. In addition, their association with cardiovascular events was investigated during a 4-year follow-up.
RESULTS: Patients in the highest tertile (T3) of serum free IS showed lower serum 1,25(OH)2D compared to patients in the middle (T2) and lowest tertile (T1); in addition to this, T3 patients showed lower serum irisin than T1 patients and lower serum PTH than all the other subjects (T1 + T2) combined. Serum PTH was also measured during the two years after the baseline measurement and was higher in patients in the T1 than in those in the T3 of serum free IS. Cox regression analysis showed that cardiovascular risk was lower in T1 patients than in those in the T3 of serum free PCS, both using a univariate (OR 2.55, 95% CI 1.2-5.43; p = 0.015) or multivariate model (OR 2.48, 95% CI 1.12-5.51; p = 0.003).
CONCLUSIONS: Serum free IS may be associated with PTH and 1,25(OH)2D secretion, whereas free PCS may predict cardiovascular risk in hemodialysis patients.
© 2022. The Author(s) under exclusive licence to Italian Society of Nephrology.

Entities:  

Keywords:  Cardiovascular outcome; Indoxyl sulfate; PTH; p-Cresyl sulfate

Mesh:

Substances:

Year:  2022        PMID: 35175580     DOI: 10.1007/s40620-022-01271-7

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   4.393


  31 in total

1.  Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.

Authors:  Sophie Liabeuf; Daniela V Barreto; Fellype C Barreto; Natalie Meert; Griet Glorieux; Eva Schepers; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  Nephrol Dial Transplant       Date:  2009-11-13       Impact factor: 5.992

Review 2.  Uremic Toxins and their Relation to Dialysis Efficacy.

Authors:  William R Clark; Nader Laal Dehghani; Vivek Narsimhan; Claudio Ronco
Journal:  Blood Purif       Date:  2019-09-27       Impact factor: 2.614

3.  Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling.

Authors:  Toshiaki Nakano; Shunsuke Katsuki; Mingxian Chen; Julius L Decano; Arda Halu; Lang Ho Lee; Diego V S Pestana; Angelo S T Kum; Rodrigo K Kuromoto; Whitney S Golden; Mario S Boff; Gabriel C Guimaraes; Hideyuki Higashi; Kevin J Kauffman; Takashi Maejima; Takehiro Suzuki; Hiroshi Iwata; Albert-László Barabási; Jon C Aster; Daniel G Anderson; Amitabh Sharma; Sasha A Singh; Elena Aikawa; Masanori Aikawa
Journal:  Circulation       Date:  2019-01-02       Impact factor: 29.690

4.  Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.

Authors:  Tessa Gryp; Kim De Paepe; Raymond Vanholder; Frederiek-Maarten Kerckhof; Wim Van Biesen; Tom Van de Wiele; Francis Verbeke; Marijn Speeckaert; Marie Joossens; Marie Madeleine Couttenye; Mario Vaneechoutte; Griet Glorieux
Journal:  Kidney Int       Date:  2020-02-17       Impact factor: 10.612

Review 5.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

6.  Tubular Secretion in CKD.

Authors:  Astrid M Suchy-Dicey; Thomas Laha; Andrew Hoofnagle; Rick Newitt; Tammy L Sirich; Timothy W Meyer; Ken E Thummel; N David Yanez; Jonathan Himmelfarb; Noel S Weiss; Bryan R Kestenbaum
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

7.  Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Authors:  Fellype C Barreto; Daniela V Barreto; Sophie Liabeuf; Natalie Meert; Griet Glorieux; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 8.237

8.  Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease.

Authors:  Cheng-Jui Lin; Hsuan-Liang Liu; Chi-Feng Pan; Chih-Kuang Chuang; Thanasekaran Jayakumar; Tuen-Jen Wang; Han-Hsiang Chen; Chih-Jen Wu
Journal:  Arch Med Res       Date:  2012-08-08       Impact factor: 2.235

9.  Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption.

Authors:  Kenta Watanabe; Tsukasa Tominari; Michiko Hirata; Chiho Matsumoto; Junya Hirata; Gillian Murphy; Hideaki Nagase; Chisato Miyaura; Masaki Inada
Journal:  FEBS Open Bio       Date:  2017-07-20       Impact factor: 2.693

10.  Phenyl sulfate, indoxyl sulfate and p-cresyl sulfate decrease glutathione level to render cells vulnerable to oxidative stress in renal tubular cells.

Authors:  Takeo Edamatsu; Ayako Fujieda; Yoshiharu Itoh
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.